true

BD Phoenix™ panels

Accurate and rapid susceptibility results

identification-mic-panels_RC_DS_IDS_0916-0021
identification-mic-panels_RC_DS_IDS_0916-0022
identification-panels_RC_DS_IDS_0916-0019
mic-panels_RC_DS_IDS_0916-0020
phoenix-system_C_DS_IDS_0616-0003
Loading
Overview

The BD Phoenix™ system offers a variety of identification only, susceptibility only and combination identification and susceptibility panels. BD Phoenix™ panels provide accurate, rapid identification and susceptibility results for most clinically significant aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria, as well as identification of yeast and yeast-like organisms.

true
Features and Benefits
Trusted performance

The BD Phoenix™ system provides on-panel doubling dilutions and built-in detection resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.

Ease of use

BD Phoenix™ panels can be stored at room temperature, are leak-resistant and do not require reagent additions post inoculation.

Emerging resistance detection

The BD Phoenix™ Emerge™ Gram-negative and Gram-positive panels offer 136 wells for susceptibility testing, allowing for additional antimicrobial dilutions that help provide the foundation for detecting emerging resistance.

Detecting Carbapenamase producing organisms (CPOs)

The BD Phoenix™ CPO detect test, offered on certain Gram-negative panels, provides information, including Ambler classification, to clinicians to help guide their treatment decisions.

Dual growth detection technology

BD Phoenix™ panels allow the BD Phoenix™ M50 instrument to determine growth using both an oxidation-reduction reaction and turbidity development, providing both rapid and accurate susceptibility results.

True doubling dilutions

The BD Phoenix™ system utilizes on-panel doubling dilutions of antimicrobial concentrations for determination of MIC results.

Multiple panel formats

BD Phoenix™ panels, which require no refrigeration and are leak resistant, are available in a variety of formats including identification-only and susceptibility-only, and in combination identification and susceptibility panels.

Largest number of wells per panel

With 136 wells dedicated to susceptibility testing, the BD Phoenix™ Emerge™ panel may allow for additional antimicrobial dilutions or additional drugs.

Resistance detection

The BD Phoenix™ system provides on-panel doubling dilutions of antimicrobials and built-in detection of resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.

*Depending on BD Phoenix™ panel type and organism identification.

Automated panel inoculation preparation

The BD Phoenix™ AP automated inoculation preparation instrument may help to reduce sample preparation workflow burdens, reducing total hands-on time per sample by 50% compared to manual BD Phoenix™ preparation and by an average of 20% compared to selected competitive products.1-2

Microorganism identification

  • The BD Phoenix™ system offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
  • The instrument can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.

Susceptibility testing

  • The BD Phoenix™ system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
  • The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
  • The BD Phoenix™ system panels test for several resistance markers*such as**:
    • Gram-positive bacteria
      • HLAR—High Level Aminoglycoside Resistant Enterococcus
      • iMLSb—Inducible Clindamycin Resistance
      • MRSA—based on Oxacillin Interpretation with Staphylococcus species
      • mecA - detection in mecA-mediated resistance Staphylococcus Aureus
      • BL-Staphylococcus ß-Lactamase (Nitrocefin-based test)
      • VRSA—Vancomycin-Resistant Staphylococcus Aureus
      • VRE—based on Vancomycin interpretation
    • Gram-negative bacteria
      • CPO—Carbapenemase Producing Organism
      • ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation

* Depending on BD Phoenix™ panel type and organism identification.

Detecting CPOs

  • The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
  • This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
    • 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
    • 9-well configuration—provides detection of Carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
  • The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
  • On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours**.

**BD internal studies—data on file

Resources
References
false
Reference
Notes
 
  1. Junkins A, et al. Comparison of BD Phoenix™ AP Workflow with Vitek 2. J. Clin. Microbiol. 2010. 48 (5): 1929-1931. – Study was a supported grant from BD Diagnostic Systems
  2. Jungkind D, et al. Workflow evaluation of the BD Phoenix™ AP Compared to the MicroScan Walkaway overnight system for identification and susceptibility testing of bacteria. As presented at the 110th General Meeting of the American Society of Microbiology. May 2010. – Study was a supported grant from BD Diagnostic Systems
true